AGGF1 anticorps

N° du produit ABIN2192195

Détail du produit anti-AGGF1 anticorps

Antigène: AGGF1 (Angiogenic Factor with G Patch and FHA Domains 1 (AGGF1))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp AGGF1 est non-conjugé

Application: Western Blotting (WB), Immunoprecipitation (IP), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunoassay (IA)

Stérilité: 0.2 μm filtered

Information d'application

Indications d'application: For Western blotting and immunohistology dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:10.

Restrictions: For Research Use only

Stockage

Buffer: PBS, containing 0.02 % sodium azide and 0.1 % bovine serum albumin.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.

Date de péremption: 12 months

Détails sur AGGF1

Antigène: AGGF1 (Angiogenic Factor with G Patch and FHA Domains 1 (AGGF1))

Autre désignation: Vg5q (AGGF1 Produits)

Synonymes: anticorps RGD1310888, anticorps AGGF1, anticorps LOC100037685, anticorps im:7146636, anticorps zgc:152959, anticorps DKFZp459G1317, anticorps GPATC7, anticorps GPATCH7, anticorps HSU84971, anticorps HUS84971, anticorps VG5Q, anticorps 2010009L17Rik, anticorps 2310029P06Rik, anticorps AW112072, anticorps Peg3, anticorps angiogenic factor with G patch and FHA domains 1, anticorps angiogenic factor with G-patch and FHA domains 1, anticorps Aggf1, anticorps AGGF1, anticorps aggf1, anticorps CC1G_06398

Sujet: The polyclonal antibody reacts with human VG5Q, a 84 kDa protein. VG5Q functions as an angiogenic factor in promoting angiogenesis and suppression of VG5Q expression inhibits vessel formation. Angiogenic factors are critical to the initiation of angiogenesis and maintenance of the vascular network. Angiogenesis has an essential role in pathological conditions such as cancer and various ischaemic and inflammatory diseases. VG5Q can bind to endothelial cells and promote cell proliferation, suggesting that the protein may act in an autocrine fashion. VG5Q interacts with TWEAK (also known as TNFSF12), another secreted angiogenic factor. VG5Q shows strong expression in blood vessels and is secreted when vessel formation is initiated. VG5Q protein was detected mostly in the cytoplasm and around the nuclei of human microvascular endothelial cells (HMVECs). Furthermore VG5Q is detected in human umbilical vein endothelial cells (HUVECs), human heart fibroblast (HHF) and ovarian cancer cells (OV-3), but low expression was detected in kidney cancer cells (RP-45), HeLa Cells and bladder cancer cells.